{"id":85926,"date":"2023-06-27T08:39:08","date_gmt":"2023-06-27T06:39:08","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/?p=85926"},"modified":"2025-10-13T15:25:02","modified_gmt":"2025-10-13T13:25:02","slug":"onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/","title":{"rendered":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac"},"content":{"rendered":"

Onechain Immunotherapeutics<\/a> (OCI), compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica centrada en el desarrollo de candidatos CAR-T para el tratamiento de enfermedades oncol\u00f3gicas e instalada en el Parque Cient\u00edfico de Barcelona<\/a>, ha anunciado el cierre de una ronda de financiaci\u00f3n pre-serie A de 6,7 M\u20ac. Los recursos obtenidos ser\u00e1n utilizados para llevar sus productos a los pacientes y finalizar el ensayo cl\u00ednico que tienen en marcha<\/strong>. Esta financiaci\u00f3n llega tres a\u00f1os despu\u00e9s de la creaci\u00f3n de la empresa, tiempo en el que ha logrado llevar a ensayo cl\u00ednico su producto m\u00e1s avanzado. <\/strong><\/p>\n

La operaci\u00f3n ha estado liderada por la gestora de capital riesgo Invivo Capital, con la participaci\u00f3n de los actuales inversores, la Fundaci\u00f3n Josep Carreras contra la leucemia y el Centro para el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n, a trav\u00e9s de su Programa Innvierte. Adem\u00e1s, ha contado con el respaldo de dos nuevos inversores, Nara Capital y Clave Capital.<\/p>\n

Onechain Immunotherapeutics (OCI) fue creada en junio de 2020 como spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras (IJC)<\/a> en una clara apuesta por acercar a los pacientes la investigaci\u00f3n del grupo liderado por el Dr. Pablo Men\u00e9ndez<\/strong>, profesor de investigaci\u00f3n ICREA e Investigador Principal del IJC. Desde entonces, la empresa ha conseguido llegar a la cl\u00ednica en menos de tres a\u00f1os y ha reforzado su pipeline con una nueva plataforma alog\u00e9nica, un programa contra tumores hematol\u00f3gicos y otro contra tumores s\u00f3lidos.<\/p>\n

\u201cNuestra compa\u00f1\u00eda es un claro ejemplo de colaboraci\u00f3n p\u00fablico-privada en beneficio de los pacientes\u201d, se\u00f1ala Jorge Alemany<\/strong>, CEO de la empresa. \u201cEs una muestra de c\u00f3mo la iniciativa de una Fundaci\u00f3n sin \u00e1nimo de lucro, con el liderazgo de inversores privados y el apoyo de la administraci\u00f3n, puede generar beneficio para los pacientes, crear empleo y hacer avanzar la ciencia\u201d.<\/p>\n

Este hito representa un avance considerable para la compa\u00f1\u00eda, que utilizar\u00e1 la financiaci\u00f3n obtenida para consolidar su l\u00ednea de productos y llevar sus innovadoras soluciones a fase cl\u00ednica. \u201cAdem\u00e1s, nos permitir\u00e1 finalizar el ensayo CARxALL, donde se est\u00e1 evaluando nuestro producto m\u00e1s avanzado\u201d, a\u00f1ade Alemany.<\/p>\n

El abordaje de OCI al tratamiento del c\u00e1ncer est\u00e1 basado en la tecnolog\u00eda CAR-T, que permite la modificaci\u00f3n gen\u00e9tica de las c\u00e9lulas T del paciente para que sean capaces de reconocer y destruir las c\u00e9lulas cancerosas. Esta tecnolog\u00eda, aunque ya consolidada en el tratamiento de ciertas leucemias y linfomas, es pionera en el tratamiento de leucemias de tipo T y tumores s\u00f3lidos, y representa una nueva esperanza para pacientes con pocas opciones de tratamiento.<\/p>\n

\u201cEstamos convencidos del enorme potencial que las terapias CAR-T representan para el tratamiento del c\u00e1ncer y, por ello, apoyamos firmemente los avances que OCI est\u00e1 logrando en este campo\u201d, afirma Laura Rodriguez<\/strong>, principal en Invivo y consejera de OneChain. \u201cLa compa\u00f1\u00eda es un claro ejemplo de transferencia tecnol\u00f3gica en terapias avanzadas, que ha logrado llevar su primer producto de investigaci\u00f3n a ensayo cl\u00ednico en menos de tres a\u00f1os\u201d, contin\u00faa.<\/p>\n

La participaci\u00f3n de nuevos inversores en la ronda de financiaci\u00f3n es tambi\u00e9n un reflejo de este \u00e9xito, ya que no solo refuerzan la posici\u00f3n financiera de la compa\u00f1\u00eda, sino que validan su progreso y el potencial de su propuesta terap\u00e9utica. \u201cQueremos dar la bienvenida a los nuevos inversores, que han confiado en la capacidad traslacional del equipo de OneChain, y que nos acompa\u00f1ar\u00e1n en esta nueva etapa para consolidar un porfolio de productos en terapia celular con el objetivo de mejorar la vida de los pacientes\u201d, concluye Rodr\u00edguez<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Onechain Immunotherapeutics (OCI), compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica centrada en el desarrollo de candidatos CAR-T para el tratamiento de enfermedades oncol\u00f3gicas e instalada en el Parque Cient\u00edfico de Barcelona, ha…<\/p>\n","protected":false},"author":11,"featured_media":85927,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[],"class_list":["post-85926","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas"],"acf":[],"yoast_head":"\nOneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Onechain Immunotherapeutics (OCI), compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica centrada en el desarrollo de candidatos CAR-T para el tratamiento de enfermedades oncol\u00f3gicas e instalada en el Parque Cient\u00edfico de Barcelona, ha...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-27T06:39:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:25:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"948\" \/>\n\t<meta property=\"og:image:height\" content=\"347\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Iuris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Iuris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/\"},\"author\":{\"name\":\"Iuris\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"headline\":\"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac\",\"datePublished\":\"2023-06-27T06:39:08+00:00\",\"dateModified\":\"2025-10-13T13:25:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/\"},\"wordCount\":643,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/onechain-1.jpg\",\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/\",\"name\":\"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/onechain-1.jpg\",\"datePublished\":\"2023-06-27T06:39:08+00:00\",\"dateModified\":\"2025-10-13T13:25:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/onechain-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/onechain-1.jpg\",\"width\":948,\"height\":347},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\",\"name\":\"Iuris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"caption\":\"Iuris\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminiuris\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/","og_locale":"es_ES","og_type":"article","og_title":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona","og_description":"Onechain Immunotherapeutics (OCI), compa\u00f1\u00eda biotecnol\u00f3gica en fase cl\u00ednica centrada en el desarrollo de candidatos CAR-T para el tratamiento de enfermedades oncol\u00f3gicas e instalada en el Parque Cient\u00edfico de Barcelona, ha...","og_url":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2023-06-27T06:39:08+00:00","article_modified_time":"2025-10-13T13:25:02+00:00","og_image":[{"width":948,"height":347,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg","type":"image\/jpeg"}],"author":"Iuris","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Iuris","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/"},"author":{"name":"Iuris","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"headline":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac","datePublished":"2023-06-27T06:39:08+00:00","dateModified":"2025-10-13T13:25:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/"},"wordCount":643,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg","articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/","url":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/","name":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg","datePublished":"2023-06-27T06:39:08+00:00","dateModified":"2025-10-13T13:25:02+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/06\/onechain-1.jpg","width":948,"height":347},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/onechain-immunotherapeutics-cierra-una-ronda-de-inversion-pre-serie-a-de-67-millones-de-euros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"OneChain Immunotherapeutics cierra una ronda pre-serie A de 6,7 M\u20ac"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d","name":"Iuris","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","caption":"Iuris"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminiuris\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/85926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=85926"}],"version-history":[{"count":8,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/85926\/revisions"}],"predecessor-version":[{"id":87755,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/85926\/revisions\/87755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/85927"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=85926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=85926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=85926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}